SG
Simeon George (Director) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in CRISPR Therapeutics AG (CRSP). Across 1 priced purchase filing, the average 21-session return was -6.3% from execution and -8.9% from disclosure (delay-adjusted; derived). The largest single filing was $27.2M of ADRX (1,600,000 sh across 3 lots, as filed), executed Sep 28. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-6.3%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-8.9%
same 1 filings, from disclosure
Filings, ttm
2
1 buys · 1 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$27.9M
shares × price, as filed
Last traded
Oct 14
Filed Oct 16
Median ADV $94.8M across their filed names
Open performance→Volume by month
Buys $78.7M
Sells $720K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
CRSPRecent filings
CRSPSALE
CRISPR Therapeutics AG
View filing →
$720K14,514 sh × $49.63
Exec Oct 14
Filed Oct 16 · 5:45 PM ET ADRXPURCHASE ADARx Pharmaceuticals, Inc. View filing → $27.2M
1,600,000 sh across 3 lots
Exec Sep 28
Filed Sep 29 · 9:43 PM ET CRSPPURCHASE CRISPR Therapeutics AG View filing → $51.5M
989,812 sh across 3 lots
Exec Jul 16 2025
Filed Jul 17 2025 · 5:19 PM ET